Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alamar Biosciences, Inc.ALMR · Entity 1791 | Chief Financial Officer | April 16, 2026 | April 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alamar Biosciences, Inc.
Report date April 16, 2026 · Filed April 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,220 |
Reported balance
After 2026-04-20 transaction · row 1
1 source rowRow 1 · 2026-04-20 · Grant · Acquired 37,220 · Balance 37,220 F1: Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2036-04-15 | Direct | 163,358 |
Reported balance
After 2026-04-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-16 · Grant · Acquired 163,358 · Balance 163,358 F2: Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.62 · Expires 2035-10-14 | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-20 · Other · Disposed 570,719 · Balance 0 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F4: Twenty-five percent of the shares subject to the option vest on October 13, 2026, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.62 · Expires 2035-10-14 | Direct | 570,719 |
Reported balance
After 2026-04-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-20 · Other · Acquired 570,719 · Balance 570,719 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F4: Twenty-five percent of the shares subject to the option vest on October 13, 2026, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date.
F2: Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date.
F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock.
F4: Twenty-five percent of the shares subject to the option vest on October 13, 2026, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
10x Genomics, Inc.
Report date August 22, 2024 · Filed August 26, 2024
Section 16 reporting ended · disclosed 2024-08-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 143,242 |
Reported balance
After 2024-08-22 transaction · row 1
1 source rowRow 1 · 2024-08-22 · Sale · Disposed 2,961 · Balance 143,242 F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2021 Filed Nov 3, 2021 23:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001567619-21-019299 · doc1.xml · derivative · entry 7 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,159 Underlying: Class A Common Stock · 10,000 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F7 · derivative.exercise_date: This option, originally for 600,000 shares, of which 229,841 shares have been exercised, vested as to 1/4th of the shares on October 8, 2019 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $164.96 | $32,992.40 |
DisclosureSEC source: 0001567619-21-019299 · doc1.xml · nonDerivative · entry 6 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,100 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $164.81 to $165.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,333 | $164.05 | $710,846.85 |
DisclosureSEC source: 0001567619-21-019299 · doc1.xml · nonDerivative · entry 5 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,300 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $163.65 to $164.62. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,667 | $163.34 | $762,314.31 |
DisclosureSEC source: 0001567619-21-019299 · doc1.xml · nonDerivative · entry 4 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,633 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $162.65 to $163.645. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500 | $162.16 | $81,078.85 |
DisclosureSEC source: 0001567619-21-019299 · doc1.xml · nonDerivative · entry 3 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,300 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $161.52 to $162.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $160.48 | $48,142.50 |
DisclosureSEC source: 0001567619-21-019299 · doc1.xml · nonDerivative · entry 2 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,800 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $160.03 to $160.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 10,000 | $5.04 | $50,400.00 |
DisclosureSEC source: 0001567619-21-019299 · doc1.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001567619-21-017949 · doc1.xml · derivative · entry 6 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,159 Underlying: Class A Common Stock · 10,000 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F6 · derivative.exercise_date: This option, originally for 600,000 shares, of which 219,841 shares have been exercised, vested as to 1/4th of the shares on October 8, 2019 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,200 | $144.57 | $173,484.96 |
DisclosureSEC source: 0001567619-21-017949 · doc1.xml · nonDerivative · entry 5 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,100 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $144.325 to $145.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,666 | $143.79 | $814,724.91 |
DisclosureSEC source: 0001567619-21-017949 · doc1.xml · nonDerivative · entry 4 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,300 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $143.30 to $144.275. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,500 | $142.80 | $357,007.75 |
DisclosureSEC source: 0001567619-21-017949 · doc1.xml · nonDerivative · entry 3 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,966 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $142.25 to $143.24. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 634 | $141.96 | $90,003.27 |
DisclosureSEC source: 0001567619-21-017949 · doc1.xml · nonDerivative · entry 2 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,466 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $141.25 to $142.24. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 10,000 | $5.04 | $50,400.00 |
DisclosureSEC source: 0001567619-21-017949 · doc1.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 23:54 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-21-054900 · doc4.xml · derivative · entry 7 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,159 Underlying: Class A Common Stock · 10,000 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · derivative.exercise_date: This option, originally for 600,000 shares, of which 209,841 shares have been exercised, vested as to one-fourth of the shares on October 8, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 23:54 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,540 | $178.80 | $275,358.31 |
DisclosureSEC source: 0001209191-21-054900 · doc4.xml · nonDerivative · entry 6 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,100 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $178.41 to $179.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 23:54 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,747 | $177.87 | $844,359.33 |
DisclosureSEC source: 0001209191-21-054900 · doc4.xml · nonDerivative · entry 5 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,640 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $177.41 to $178.36. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 23:54 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,200 | $177.00 | $389,396.04 |
DisclosureSEC source: 0001209191-21-054900 · doc4.xml · nonDerivative · entry 4 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,387 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $176.39 to $177.355. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 23:54 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,139 | $175.95 | $200,411.83 |
DisclosureSEC source: 0001209191-21-054900 · doc4.xml · nonDerivative · entry 3 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,587 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $175.34 to $176.285. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 23:54 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 374 | $174.87 | $65,401.38 |
DisclosureSEC source: 0001209191-21-054900 · doc4.xml · nonDerivative · entry 2 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,726 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $174.20 to $175.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 23:54 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 10,000 | $5.04 | $50,400.00 |
DisclosureSEC source: 0001209191-21-054900 · doc4.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| August 23, 2021 Filed Aug 26, 2021 00:37 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 270 | $161.85 | $43,698.83 |
DisclosureSEC source: 0001209191-21-053392 · doc4.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,100 F1 · shares: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:46 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-21-049650 · doc4.xml · derivative · entry 9 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,159 Underlying: Class A Common Stock · 10,000 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · derivative.exercise_date: This option, originally for 600,000 shares, of which 199,841 shares have been exercised, vested as to one-fourth of the shares on October 8, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:46 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $184.52 | $55,356.99 |
DisclosureSEC source: 0001209191-21-049650 · doc4.xml · nonDerivative · entry 8 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,370 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $184.19 to $184.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:46 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500 | $183.30 | $91,650.00 |
DisclosureSEC source: 0001209191-21-049650 · doc4.xml · nonDerivative · entry 7 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,670 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $182.93 to $183.62. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:46 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 700 | $182.16 | $127,514.03 |
DisclosureSEC source: 0001209191-21-049650 · doc4.xml · nonDerivative · entry 6 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,170 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $181.93 to $182.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:46 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,302 | $181.31 | $417,375.85 |
DisclosureSEC source: 0001209191-21-049650 · doc4.xml · nonDerivative · entry 5 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,870 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $180.89 to $181.87. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:46 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,298 | $180.29 | $414,304.12 |
DisclosureSEC source: 0001209191-21-049650 · doc4.xml · nonDerivative · entry 4 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,172 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $179.89 to $180.865. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:46 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,202 | $179.28 | $394,780.07 |
DisclosureSEC source: 0001209191-21-049650 · doc4.xml · nonDerivative · entry 3 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,470 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $178.865 to $179.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:46 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,698 | $178.35 | $302,839.83 |
DisclosureSEC source: 0001209191-21-049650 · doc4.xml · nonDerivative · entry 2 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,672 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $177.80 to $178.74. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:46 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 10,000 | $5.04 | $50,400.00 |
DisclosureSEC source: 0001209191-21-049650 · doc4.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:29 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-21-045475 · doc4.xml · derivative · entry 9 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,159 Underlying: Class A Common Stock · 10,000 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · derivative.exercise_date: This option, originally for 600,000 shares, of which 189,841 shares have been exercised, vested as to one-fourth of the shares on October 8, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:29 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $195.82 | $19,582.00 |
DisclosureSEC source: 0001209191-21-045475 · doc4.xml · nonDerivative · entry 8 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,370 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:29 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 700 | $194.81 | $136,363.78 |
DisclosureSEC source: 0001209191-21-045475 · doc4.xml · nonDerivative · entry 7 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,470 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $194.40 to $195.39. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:29 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,400 | $193.76 | $271,268.06 |
DisclosureSEC source: 0001209191-21-045475 · doc4.xml · nonDerivative · entry 6 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,170 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $193.38 to $194.35. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:29 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 800 | $192.95 | $154,357.84 |
DisclosureSEC source: 0001209191-21-045475 · doc4.xml · nonDerivative · entry 5 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,570 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $192.32 to $193.31. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:29 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,500 | $191.73 | $287,602.05 |
DisclosureSEC source: 0001209191-21-045475 · doc4.xml · nonDerivative · entry 4 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,370 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $191.32 to $192.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:29 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,800 | $190.66 | $533,858.64 |
DisclosureSEC source: 0001209191-21-045475 · doc4.xml · nonDerivative · entry 3 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,870 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $190.25 to $191.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:29 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,700 | $189.85 | $512,600.94 |
DisclosureSEC source: 0001209191-21-045475 · doc4.xml · nonDerivative · entry 2 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,670 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $189.24 to $190.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:29 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 10,000 | $5.04 | $50,400.00 |
DisclosureSEC source: 0001209191-21-045475 · doc4.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · balance_after: Includes an aggregate of 359 shares previously acquired under the Issuer's 2019 Employee Stock Purchase Plan. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 22:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-21-037902 · doc4.xml · derivative · entry 10 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,159 Underlying: Class A Common Stock · 10,000 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F10 · derivative.exercise_date: This option, originally for 600,000 shares, of which 179,841 shares have been exercised, vested as to one-fourth of the shares on October 8, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 22:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $180.02 | $54,006.99 |
DisclosureSEC source: 0001209191-21-037902 · doc4.xml · nonDerivative · entry 9 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,011 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · price: This transaction was executed in multiple trades at prices ranging from $179.97 to $180.10. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 22:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $179.21 | $35,841.50 |
DisclosureSEC source: 0001209191-21-037902 · doc4.xml · nonDerivative · entry 8 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,311 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $178.92 to $179.39. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 22:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $178.07 | $53,420.01 |
DisclosureSEC source: 0001209191-21-037902 · doc4.xml · nonDerivative · entry 7 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,511 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $177.65 to $178.60. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 22:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,906 | $175.77 | $510,786.17 |
DisclosureSEC source: 0001209191-21-037902 · doc4.xml · nonDerivative · entry 6 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,811 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $175.42 to $176.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 22:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,994 | $174.93 | $348,807.63 |
DisclosureSEC source: 0001209191-21-037902 · doc4.xml · nonDerivative · entry 5 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,717 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $174.38 to $175.37. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 22:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,000 | $173.94 | $173,944.00 |
DisclosureSEC source: 0001209191-21-037902 · doc4.xml · nonDerivative · entry 4 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,711 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $173.36 to $174.31. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 22:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 800 | $172.85 | $138,278.56 |
DisclosureSEC source: 0001209191-21-037902 · doc4.xml · nonDerivative · entry 3 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,711 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $172.25 to $173.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 22:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,500 | $171.59 | $428,984.50 |
DisclosureSEC source: 0001209191-21-037902 · doc4.xml · nonDerivative · entry 2 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,511 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $171.12 to $172.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 22:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 10,000 | $5.04 | $50,400.00 |
DisclosureSEC source: 0001209191-21-037902 · doc4.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| May 24, 2021 Filed May 27, 2021 00:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 281 | $162.66 | $45,707.35 |
DisclosureSEC source: 0001209191-21-036102 · doc4.xml · nonDerivative · entry 2 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,011 F3 · shares: These shares were sold to cover tax withholding obligations in connection with the vesting of RSUs. F4 · balance_after: The number of shares beneficially owned following the reported transaction is as of May 24, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.